Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.


GlobeNewswire Inc | Aug 15, 2020 10:10PM EDT

August 16, 2020

NEW YORK, Aug. 15, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 29, 2020, Verrica announced receipt of a letter from the U.S. Food and Drug Administration (FDA) as part of the FDAs ongoing review of the Companys New Drug Application (NDA) for VP-102 (cantharidin 0.7% topical solution), Verricas lead product candidate for the treatment of molluscum contagiosum. According to the Company, the letter cited deficiencies that precluded discussion of labeling and post-marketing requirements/commitments at that time.

Following this announcement, Verricas stock price fell $3.06 per share, or 21.75%, to close at $11.01 per share on June 30, 2020.

Then, on July 14, 2020, Verrica announced receipt of a Complete Response Letter (CRL) from the FDA regarding the NDA for VP-102, advising Verrica that the FDA is seeking additional information regarding certain aspects of the CMC (Chemistry, Manufacturing, and Controls) process for the drug/device combination, as well as Human Factors validation.

Following Verricas disclosure of the CRL, the Companys stock price fell sharply during intraday trading on July 14, 2020, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com888-476-6529 ext. 7980







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC